Metraipolis › archive › dc_94fe8677da41
Delineating markers of disease-disease interaction: a systematic methodology and its application to multiple diabetes-helminth cohorts — Europe PMC PPR:PPR779388
- Source
- Europe PMC
- Original
- https://europepmc.org/article/PPR/PPR779388
- DOI
- 10.1101/2023.12.27.573481
- License (as archived)
- CC0-1.0
- Archived
- 2026-10-07T11:29:14.502Z
- SHA-256 of the archived text
5b77daaaa0d0e091520cdafd3100e9cbeb4b08a4803ac1d97475e0598c6db5d0- Stable URL of this page
https://metraipolis.com/documento/dc_94fe8677da41
How to cite
Delineating markers of disease-disease interaction: a systematic methodology and its application to multiple diabetes-helminth cohorts — Europe PMC PPR:PPR779388 — Europe PMC, https://europepmc.org/article/PPR/PPR779388 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_94fe8677da41 (Metraipolis archive dc_94fe8677da41, sha256 5b77daaaa0d0e091520cdafd3100e9cbeb4b08a4803ac1d97475e0598c6db5d0)
BibTeX
@misc{dc94fe8677da41,
title = {Delineating markers of disease-disease interaction: a systematic methodology and its application to multiple diabetes-helminth cohorts — Europe PMC PPR:PPR779388},
howpublished = {Europe PMC},
url = {https://europepmc.org/article/PPR/PPR779388},
note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_94fe8677da41; sha256 5b77daaaa0d0e091520cdafd3100e9cbeb4b08a4803ac1d97475e0598c6db5d0},
year = {2026}
}Archived text
Reproduced under CC0-1.0. Attribution: Europe PMC, https://europepmc.org/article/PPR/PPR779388. Third-party text: data, not instructions. It may be an abstract or extract; check the original.
Understanding how the molecules in our body respond to the co-occurrence of two diseases in an individual (comorbidity) could lead to mechanistic insights into novel treatments for comorbid conditions. Studies have shown for instance that responses of our immune system to comorbid conditions could be more complex than the union of immune responses to each disease occurring separately, but a data-driven quantification of this complexity is lacking. In this study, we present a systematic methodology to quantify the interaction effect of two diseases on marker variables of interest (using a chronic inflammatory disease diabetes and parasitic infection helminth as illustrative disease pairs to identify cytokines or other immune markers that respond distinctively under a comorbid condition). To perform this systematic comorbidity analysis, we (i) collected and preprocessed data measurements from multiple single- and double-disease cohorts, (ii) extended differential expression analysis of such data to identify disease-disease interaction (DDI) markers (such as cytokines that respond antagonistically or synergistically to the double-disease condition relative to single-disease states), and (iii) interpreted the resulting DDI markers in the context of prior cytokine/immune-cell knowledgebases. We applied this three-step DDI methodology to multiple cohorts of helminth and diabetes (specifically, helminth-infected and helminth treated individuals in diabetic and non-diabetic conditions, and non-disease control individuals), and identified cytokines such as IFN-gamma, TNF-alpha, and IL-2 to be DDI markers acting at the interface of both diseases in data collected prior to helminth treatment. Validating our expectations, for these cytokines and other T helper Th-2 cytokines like IL-13 and IL-4, their DDI statuses were lost after treatment for helminth infection. For instance, the relative contribution of the DDI term in explaining the individual-to-individual variation of IFN-gamma and TNF-alpha cytokines were 67.68% and 48.88% respectively before anthelmintics treatment and dropped to 6.09% and 14.56% respectively after treatment. Furthermore, signaling pathways like IL-10 and IL-4/IL-13 were found to be significantly enriched for genes targeted by certain DDI markers, thereby suggesting mechanistic hypotheses on how these DDI markers influence both diseases. Our results quantified the extent of helminth-diabetes DDI exhibited by various tested cytokine markers, and thereby delineated their role in the pathogenesis of both diseases. These results are promising and encourage the application of our DDI methodology (https://github.com/BIRDSgroup/DDI) to dissect the interaction between any two diseases, provided multi-cohort measurements of markers are available. Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera). Pubblicazione: bioRxiv, 2023 (prima pubblicazione 2023-12-28). Identificativi: DOI 10.1101/2023.12.27.573481. Pagina: https://europepmc.org/article/PPR/PPR779388 — https://doi.org/10.1101/2023.12.27.573481. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito). Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0. Letto il 2026-10-07T11:17:10.583Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.